Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities
Open Access
- 21 November 2023
- journal article
- review article
- Published by Elsevier in Cell Genomics
- Vol. 4 (1) , 100444
Abstract
No abstract availableKeywords
Funding Information
- U.S. National Library of Medicine (T15LM007092)
- Dana-Farber Cancer Institute
This publication has 158 references indexed in Scilit:
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiotaScience, 2015
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacyScience, 2015
- Genomic correlates of response to CTLA-4 blockade in metastatic melanomaScience, 2015
- Estimating T-cell repertoire diversity: limitations of classical estimators and a new approachPhilosophical Transactions of the Royal Society B: Biological Sciences, 2015
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaJournal of Translational Medicine, 2011
- Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 lossLaboratory Investigation, 2009
- Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancerThe Breast, 2008
- Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancerBritish Journal of Cancer, 2008